3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow GKT137831: new trials by email Literature Review of GKT137831 trials Research Report on GKT137831
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Placebo Oral Tablet, GKT137831 - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | University of Alabama at Birmingham | 58 | 2020-09-07 | 2026-05-11 |
| Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. GKT137831, Placebo oral capsule - Primary Biliary Cirrhosis | Phase 2 | Completed | Calliditas Therapeutics AB | 111 | 2017-06-26 | 2022-06-29 |
| Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria GKT137831, Placebo - Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Completed | Calliditas Therapeutics AB | 136 | 2013-10-01 | 2025-02-28 |
Albuminuria (1) · Diabetes Mellitus, Type 2 (1) · Idiopathic Pulmonary Fibrosis (1) · Liver Cirrhosis, Biliary (1) · Proteinuria (1)
Calliditas Therapeutics AB (2) · University of Alabama at Birmingham (1)
United States (3) · Canada (2) · Germany (2) · Australia (1) · Belgium (1) · Czechia (1) · Greece (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Philippe Wiesel, MD (2) · Steven R Duncan, MD (1)
PMID 36809195, PMID 37183520, PMID 41805697
2016 (1)